問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Urology

Division of Pediatrics

Division of Hematology & Oncology

更新時間：2023-09-19

黃國皓-, -
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -4 個月

Recruiting Trial

23Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃國皓

List

64Cases

2026-05-20 - 2032-04-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2023-12-01 - 2029-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-06-01 - 2027-06-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-08-01 - 2027-05-20

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-12-01 - 2033-05-05

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting6Sites

2009-02-01 - 2010-08-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2019-05-19 - 2027-01-25

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2010-01-01 - 2013-07-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2009-05-01 - 2013-01-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2015-01-01 - 2018-12-31

Phase III

A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY

  • Condition/Disease

    Urothelial Bladder Cancer

  • Test Drug

    TECENTRIQ® (Atezolizumab)

Participate Sites
4Sites

Terminated4Sites

1 2 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB